当前位置: 首页 >> 检索结果
1361. Halving premature death and improving quality of life at all ages: cross-country analyses of past trends and future directions.
作者: Ole F Norheim.;Angela Y Chang.;Sarah Bolongaita.;Mariana Barraza-Lloréns.;Ayodamope Fawole.;Lia Tadesse Gebremedhin.;Eduardo González-Pier.;Prabhat Jha.;Emily K Johnson.;Omar Karlsson.;Mizan Kiros.;Sarah Lewington.;Wenhui Mao.;Osondu Ogbuoji.;Muhammad Pate.;Jennifer L Sargent.;Xuyang Tang.;David Watkins.;Gavin Yamey.;Dean T Jamison.;Richard Peto.
来源: Lancet. 2024年404卷10470期2437-2446页
Although death in old age is unavoidable, premature death-defined here as death before age 70 years-is not. To assess whether halving premature mortality by 2050 is feasible, we examined the large variation in premature death rates before age 70 years and trends over the past 50 years (1970-2019), covering ten world regions and the 30 most-populous nations. This analysis was undertaken in conjunction with the third report of The Lancet Commission on Investing in Health: Global Health 2050: the path to halving premature death by mid-century.
1362. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
作者: Marc Ferrante.;Geert D'Haens.;Vipul Jairath.;Silvio Danese.;Minhu Chen.;Subrata Ghosh.;Tadakazu Hisamatsu.;Jaroslaw Kierkus.;Britta Siegmund.;Sonja Michelle Bragg.;Wallace Crandall.;Frederick Durand.;Emily Hon.;Zhantao Lin.;Michelle Ugolini Lopes.;Nathan Morris.;Marijana Protic.;Hilde Carlier.;Bruce E Sands.; .
来源: Lancet. 2024年404卷10470期2423-2436页
Mirikizumab, a humanised monoclonal antibody that inhibits IL-23p19, is effective in moderate-to-severe ulcerative colitis. We aimed to evaluate the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease.
1368. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
作者: Alberto Bossi.;Stéphanie Foulon.;Xavier Maldonado.;Paul Sargos.;Ray MacDermott.;Paul Kelly.;Aude Fléchon.;Bertrand Tombal.;Stephane Supiot.;Dominik Berthold.;Philippe Ronchin.;Gabriel Kacso.;Naji Salem.;Fabio Calabro.;Jean-François Berdah.;Ali Hasbini.;Marlon Silva.;Jihane Boustani.;Hélène Ribault.;Karim Fizazi.; .
来源: Lancet. 2024年404卷10467期2065-2076页
The 2 × 2 PEACE-1 study showed that combining androgen-deprivation therapy with docetaxel and abiraterone improved overall and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. We aimed to examine the efficacy and safety of adding radiotherapy in this population.
|